Drug Profile
SM 20220
Alternative Names: SM-20220Latest Information Update: 08 Feb 2008
Price :
$50
*
At a glance
- Originator Dainippon Sumitomo Pharma
- Class Anti-ischaemics; Neuroprotectants
- Mechanism of Action Sodium hydrogen antiporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 08 Feb 2008 Discontinued - Preclinical for Neurological disorders (Prevention) in Japan (IV)
- 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
- 11 Feb 2004 A preclinical study has been added to the Neurological Disorders pharmacodynamics section